The number of annual implantable cardioverter defibrillator (ICD) implants has substantially increased over the last 5 years and is expected to grow rapidly. Implantable cardioverter defibrillators have a proven mortality benefit by terminating the life-threatening arrhythmias, even near end of life. In patients with moderate/severe symptomatic heart failure, enough clinical literature representing mortality benefits has been published, but limited numbers of studies have reviewed the dwindling risk–benefit profile near end of life, studying quality of life (QoL)/psychosocial impact. Criteria outlining either continued use or deactivation policy/procedures near end of life have not been clearly defined and/or largely implemented, which in turn requires more focused research using multifactorial approach to determine improved patient-centered outcomes.
TurakhiaMP. Sudden cardiac death and implantable cardioverter-defibrillators. Am Fam Physician. 2010; 82(11): 1357–1366.
2.
PedersenSSSearsSFBurgMMVan Den BroekKC. Does ICD indication affect quality of life and levels of distress?Pacing Clin Electrophysiol. 2009; 32(2): 153–156.
3.
GroeneveldPWMattaMASuhJJYangFSheaJA. Quality of life among implantable cardioverter-defibrillator recipients in the primary prevention therapeutic era. Pacing Clin Electrophysiol. 2007; 30(4): 463–471.
4.
PackerDLPrutkinJMHellkampAS. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009; 120(22): 2170–2106. Erratum in: Circulation. 2010; 121(6): e39.
5.
EpsteinAEDiMarcoJPEllenbogenKA. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and anti-arrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons [published correction appears in Circulation. 2009;120(5): e34-e35]. Circulation. 2008; 117(21): e350–e408.
6.
SalukheTVBricenoNIFerencziEASuttonRFrancisDP. Is there benefit in implanting defibrillators in patients with severe heart failure?Heart. 2010; 96(8): 599–603.
7.
BardyGHPooleJEKudenchukPJDolackGLKelsoDMitchellR. A prospective randomized repeat-crossover comparison of antitachycardia pacing with low-energy cardioversion. Circulation. 1993; 87(6): 1889–1896.
PinskiSLTrohmanRG. Interference in implanted cardiac devices, Part I. Pacing Clin Electrophysiol. Review. 2002; 25(9): 1367–1381.
11.
PinskiSLTrohmanRG. Interference in implanted cardiac devices, part II. Pacing Clin Electrophysiol. 2002; 25(10): 1496–1509. Review.
12.
MadiganJDChoudhriAFChenJSpotnitzHMOzMCEdwardsN. Surgical management of the patient with an implanted cardiac device: implications of electromagnetic interference. Ann Surg. 1999; 230(5): 63–47.
13.
HudsonFCoulshedDD'SouzaEBakerC. Effect of radiation therapy on the latest generation of pacemakers and implantable cardioverter defibrillators: a systematic review. J Med Imaging RadiatOncol. 2010; 54(1): 53–61. Review.
14.
RoedigJJShahJElayiCSMillerCS. Interference of cardiac pacemaker and implantable cardioverter-defibrillator activity during electronic dental device use. J Am Dent Assoc. 2010; 141(5): 521–526.
15.
SherNAGolbenMPKresgeKSelznickLAdabagS. An in vitro evaluation of electromagnetic interference between implantable cardiac devices and ophthalmic laser systems. Europace. 2011; 13(4): 583–588.
16.
DingLHuaWNiuHChenKZhangS. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators. Europace. 2008; 10(9): 1034–1041.
17.
BuxtonAELeeKLFisherJDJosephsonMEPrystowskyENHafleyG. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med. 1999; 341(25): 1882–1890. Erratum in: N Engl J Med. 2000; 342(17): 1300.
18.
MossAJZarebaWHallWJ; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346(12): 877–883.
19.
WeverEFHauerRNvan CapelleFL. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995; 91(8): 2195–2203.
20.
SiebelsJKuckKH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 1994; 127(4 pt 2): 1139–1144.
21.
ConnollySJGentMRobertsRS. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000; 101(11): 1297–1302.
22.
KuckKHCappatoRSiebelsJRüppelR. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102(7): 748–754.
23.
ConnollySJHallstromAPCappatoR. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs. Implantable Defibrillator study. cardiac arrest study hamburg. Canadian implantable defibrillator study. Eur Heart J. 2000; 21(24): 2071–2078.
24.
BardyGHLeeKLMarkDB. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352(3): 225–237. Erratum inN Engl J Med. 2005; 352(20): 2146.
25.
KadishADyerADaubertJP. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004; 350(21): 2151–2158.
26.
DesaiASFangJCMaiselWHBaughmanKL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004; 292(23): 2874–2879. Review.
27.
MossAJHallWJCannomDS. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med. 1996; 335(26): 1933–1940.
28.
ZarebaWMossAJDaubertJPHallWJRobinsonJLAndrewsM. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003; 14(4): 337–341.
29.
ViskinS. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003; 14(10): 1130–1131. Reply 1131.
30.
MönnigGKöbeJLöherA. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm. 2005; 2(5): 497–504.
31.
HobbsJBPetersonDRMossAJ. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006; 296(10): 1249–1254.
32.
TsaiFSAronowWSDevabhaktuniS. Prevalence of complications during implantation and during 38-month follow-up of 1060 consecutive patients with implantable cardioverter-defibrillators. Am J Ther. 2010; 17(1): e8–e10.
33.
EcksteinJKollerMTZabelM. Necessity for surgical revision of defibrillator leads implanted long-term: causes and management. Circulation. 2008; 117(21): 2727–2733.
KrahnADLeeDS, Birnie D, et al; for the Ontario ICD Database Investigators. Predictors of short-term complications after implantable cardioverter-defibrillator replacement: results from the ontario ICD database. Circ Arrhythm Electrophysiol. 2011; 4(2): 136–142.
37.
GoldsteinNCarlsonMLivoteEKutnerJS. Brief communication: management of implantable cardioverter-defibrillators in hospice: a nationwide survey. Ann Intern Med. 2010; 152(5): 296–299.
38.
GoldsteinNELampertRBradleyEHLynnJKrumholzHM. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med. 2004; 141(11): 835–838.
39.
SearsSFJrTodaroJFLewisTSSotileWContiJB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol. 1999; 22(7): 481–489.
40.
MorrisonLJCalvinAONoraHPorter StoreyCJr. Managing cardiac devices near the end of life: a survey of hospice and palliative care providers. Am J Hosp Palliat Care. 2010; 27(8): 545–551.
41.
SearsSFLewisTSKuhlEAContiJB. Predictors of quality of life in patients with implantable cardioverter defibrillators. Psychosomatics. 2005; 46(5): 451–457.
42.
SearsSFTodaroJFUrizarG. Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol. 2000; 23(6): 939–945.
43.
TraubDGanzL. Implantable cardioverter-defibrillators for secondary prevention: is it worth it in the elderly?Am J Geriatr Cardiol. 2006; 15(2): 93–99. quiz100–101.
44.
BadgerJMMorrisPL. Observations of a support group for automatic implantable cardioverter-defibrillator recipients and their spouses. Heart Lung. 1989; 18(3): 238–243.
45.
FitchetADohertyPJBundyCBellWFitzpatrickAPGarrattCJ. Comprehensive cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: a randomised controlled trial. Heart. 2003; 89(2): 155–160.
46.
FrizelleDJLewinRJKayeG. Cognitive-behavioural rehabilitation programme for patients with an implanted cardioverter defibrillator: a pilot study. Br J Health Psychol. 2004; 9(pt 3): 381–392.
47.
KohnCSPetrucciRJBaesslerCSotoDMMovsowitzC. The effect of psychological intervention on patients' long-term adjustment to the ICD: a prospective study. Pacing Clin Electrophysiol. 2000; 23(4 pt 1): 450–456.
48.
DoughertyCMLewisFMThompsonEABaerJDKimW. Short-term efficacy of a telephone intervention by expert nurses after an implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2004; 27(12): 1594–1602.
49.
KapaSMuellerPSHayesDLAsirvathamSJ. Perspectives on withdrawing pacemaker and implantable cardioverter-defibrillator therapies at end of life: results of a survey of medical and legal professionals and patients. Mayo Clin Proc. 2010; 85(11): 981–990.
50.
HarringtonMDLuebkeDLLewisWRAulisioMPJohnsonNJ. Cardiac pacemakers at end of life #111. J PalliatMed. 2005; 8(5): 1055–1056.
51.
ConeliusJ. A literature review: advance directives and patients with implantable cardioverter defibrillators. J Am Acad Nurse Pract. 2010; 22(5): 250–255.
52.
LampertRHayesDLAnnasGJ; American College of Cardiology; American Geriatrics Society; American Academy of Hospice and Palliative Medicine, American Heart Association; European Heart Rhythm Association; Hospice and Palliative Nurses Association. HRS expert consensus statement on the management of cardiovascular implantable electronic devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm. 2010; 7(7): 1008–1026.
53.
SearsSFMatchettMContiJB. Effective management of ICD patient psychosocial issues and patient critical events. J Cardiovasc Electrophysiol. 2009; 20(11): 1297–1304. Review.
54.
KramerDBKesselheimASBrockDWMaiselWH. Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm. 2010; 7(11): 1537–1542.
55.
LewisWRLuebkeDLJohnsonNJHarringtonMDCostantiniOAulisioMP. Withdrawing implantable defibrillator shock therapy in terminally ill patients. Am J Med. 2006;119(10): 892–896.
56.
LadwigKHIschingerNFRonelJKolbC. Treating ICD patients at the end of their lives: attitudes, knowledge, and behavior of doctors and patients: A critical literature analysis. Herzschrittmacherther Elektrophysiol. 2011; 22(3): 151–6.
